Enhabit, Inc. (NYSE:EHAB) Receives $9.35 Consensus PT from Analysts

Shares of Enhabit, Inc. (NYSE:EHAB) have received a consensus recommendation of “Reduce” from the seven ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $9.35.

Separately, Bank of America decreased their price target on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating on the stock in a research note on Thursday, June 27th.

Enhabit Trading Down 0.6 %

Shares of Enhabit stock opened at $8.00 on Friday. The firm has a market capitalization of $401.25 million, a PE ratio of -4.82 and a beta of 1.82. Enhabit has a twelve month low of $7.12 and a twelve month high of $12.61. The firm’s 50-day moving average price is $8.81 and its 200 day moving average price is $9.38. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to analyst estimates of $265.99 million. Enhabit had a negative net margin of 0.84% and a positive return on equity of 1.61%. During the same period last year, the company posted $0.04 EPS. On average, sell-side analysts predict that Enhabit will post 0.26 EPS for the current fiscal year.

Insider Buying and Selling at Enhabit

In other Enhabit news, Director Jeffrey Bolton purchased 5,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average price of $8.01 per share, with a total value of $40,050.00. Following the transaction, the director now directly owns 78,877 shares of the company’s stock, valued at approximately $631,804.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enhabit

Institutional investors have recently modified their holdings of the company. SummerHaven Investment Management LLC lifted its position in Enhabit by 2.8% in the second quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock valued at $549,000 after acquiring an additional 1,660 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in Enhabit by 7.2% in the first quarter. Oppenheimer & Co. Inc. now owns 26,224 shares of the company’s stock valued at $306,000 after purchasing an additional 1,768 shares during the period. PNC Financial Services Group Inc. increased its stake in Enhabit by 13.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the company’s stock valued at $166,000 after purchasing an additional 1,875 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Enhabit by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock valued at $443,000 after purchasing an additional 2,078 shares during the period. Finally, Quarry LP increased its stake in Enhabit by 242.2% in the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after purchasing an additional 2,621 shares during the period.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.